Ozempic and SNRIs (Venlafaxine, Duloxetine): Drug Interaction Guide

What does the Ozempic label say about drug interactions?

The Ozempic drug interactions section has two parts. The first is use with an insulin secretagogue (such as a sulfonylurea) or insulin, where hypoglycemia risk rises and a lower dose of the secretagogue or insulin may be needed [1]. The second is use with other oral medicines: Ozempic injection delays gastric emptying and may affect absorption of oral medicines, and the label advises caution, although clinical pharmacology trials found no clinically relevant effect on oral drug absorption [1].

On the antidepressant side, the Effexor XR drug interaction table covers MAOIs, other serotonergic drugs, drugs that interfere with hemostasis, CYP3A inhibitors and CYP2D6 substrates, and its other-interactions text covers CNS-active drugs and weight-loss agents [2]. Semaglutide is not among them [2].

Blood pressure: what the SNRI labels report

Venlafaxine's effect is dose related. In the Effexor XR label's trial data, sustained hypertension (supine diastolic pressure of 90 or more that was also 10 or more above baseline on three visits) occurred in 19 of 705 patients treated for major depression, or 3%, and in 0.5% with generalized anxiety, 0.6% with social anxiety and 0.9% with panic disorder [2]. A rise of at least 15 mm Hg to 105 or more occurred in 1.4% versus 0.9% on placebo, and a systolic rise of at least 20 mm Hg to 180 or more in 1% versus 0.3% [2]. Too few patients took more than 300 mg a day for the label to assess that range [2].

A meta-analysis of original data from 3,744 depressed patients in controlled trials of venlafaxine against imipramine and/or placebo found small but significant rises in supine diastolic pressure. The effect was highly dose dependent, clinically significant only above 300 mg a day in immediate-release data, and did not worsen blood pressure control in patients who already had high blood pressure [6].

The SNRI labels treat high blood pressure as a caution rather than a contraindication [2][3].

In the desvenlafaxine (Pristiq) fixed-dose depression studies, sustained diastolic hypertension occurred in 0.5% on placebo and 1.3%, 0.7%, 1.1% and 2.3% at 50, 100, 200 and 400 mg [3]. For levomilnacipran (Fetzima, 40 to 120 mg a day), mean systolic pressure rose 3.0 mm Hg versus a fall of 0.4 on placebo, diastolic rose 3.2 versus 0.0, and heart rate rose 7.4 beats per minute versus a fall of 0.3 [4].

Duloxetine looks different. Adult placebo-controlled trials showed a mean systolic rise of 0.5 and diastolic rise of 0.8 mm Hg, against falls of 0.6 and 0.3 on placebo, with no significant difference in sustained elevated blood pressure; at 200 mg twice daily, about 3.3 times the maximum recommended dose, supine pressure rose 4.7 to 6.8 mm Hg systolic and 4.5 to 7 mm Hg diastolic and pulse rose 5 to 6.8 beats per minute [5]. The duloxetine label still says to check blood pressure before starting and periodically, and it carries warnings for orthostatic hypotension, falls and syncope [5]. The Effexor XR label says to control pre-existing hypertension before starting, to measure blood pressure before and regularly during treatment, and to consider dose reduction or discontinuation if the increase is sustained [2].

On the semaglutide side, the Ozempic label's warnings cover acute pancreatitis, gallbladder disease, hypoglycemia with insulin or sulfonylureas, kidney injury from volume depletion, severe gastrointestinal reactions, hypersensitivity, diabetic retinopathy complications, pen sharing and pulmonary aspiration during anesthesia or deep sedation; blood pressure is not among them [1].

Is serotonin syndrome a risk with Ozempic plus an SNRI?

The Effexor XR label names the drugs that raise serotonin syndrome risk: triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, St John's wort and other serotonergic antidepressants, with MAOIs contraindicated outright; it also notes the syndrome can occur with an SNRI alone [2]. Semaglutide is not on those lists [2].

Symptoms listed for serotonin syndrome include agitation, hallucinations, rapid heart rate, unstable blood pressure, sweating, high temperature, tremor, rigidity, muscle jerks, overactive reflexes, seizures, nausea, vomiting and diarrhea [2].

Does semaglutide change how an SNRI is absorbed?

The Ozempic label says semaglutide delays gastric emptying and may affect absorption of oral medicines, and advises caution, adding that in clinical pharmacology trials it did not affect oral drug absorption to any clinically relevant degree [1]. Its interaction section names no SNRI [1].

Nausea on both drugs

Both drugs list nausea as a common reaction. Nausea occurred in 30.0% of Effexor XR patients versus 11.8% on placebo across its trials [2]. In pooled Ozempic trials it occurred in 15.8% on 0.5 mg and 20.3% on 1 mg versus 6.1% on placebo, with any gastrointestinal reaction in 32.7% and 36.4% versus 15.3% [1]. The labels note that rates from different trials cannot be compared directly [1][2].

Where the venlafaxine label singles out weight-loss drugs

The Effexor XR label states that concomitant use with weight-loss agents is not recommended, and that the safety and efficacy of venlafaxine with weight-loss agents, including phentermine, have not been established [2]. Ozempic is not approved for weight loss [1].

Suicidality warnings

The antidepressant labels carry a boxed warning for suicidal thoughts and behaviors in pediatric and young adult patients and say to monitor all antidepressant-treated patients for clinical worsening [2][5]. The Ozempic label carries no suicidal thoughts or behaviors warning [1].